Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

Update: 2024-09-30

Description

Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations.

Read the full Article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00264-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments

In Channel

Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3

2025-11-2525:41

Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission

2025-11-0210:46

Matthias Preusser on the phase 2 TUXEDO-3 trial

2025-10-2717:10

Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer

2025-09-2912:15

Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas

2025-09-0214:22

Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer

2025-07-2807:36

Abdalla Awidi on cancer control in the Middle East

2025-06-1108:22

ASCO 2025 Debrief

2025-06-1114:45

Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial)

2025-05-2810:45

Richard Bryant on transperineal vs transrectal biopsy for prostate cancer

2025-04-3018:02

$Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)$

Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)

2025-03-3107:33

Ariana Znaor on cancer surveillance in the Eastern Mediterranean region

2025-03-0320:03

Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials

2025-02-0318:03

Yannick Romero on the changing landscape of national cancer control plans

2025-01-0224:40

M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries

2024-12-0222:15

$Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma$

Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

2024-10-3015:07

Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

2024-09-3017:21

May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

2024-09-3040:45

Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

2024-08-2713:22

Emmy Boerrigter on dose selection of novel anticancer drugs

2024-07-2911:41

00:00

Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

#box-pro-ellipsis-176526335592235{-webkit-line-clamp:2;}Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

The Lancet Group

Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination